Abstract
The present study was conducted to compare the effectiveness and tolerability of fluoxetine and sertraline in the treatment of undifferentiated somatoform disorder (USD), using the Patient Health Questionnaire (PHQ-15), which was specifically designed for assessing the severity of somatic symptoms. A randomized, 12-week, open-label trial of fluoxetine (10-60 mg/d) and sertraline (25-350 mg/d) in patients with USD was conducted. Six visits, at baseline and weeks 1, 2, 4, 8, and 12, were scheduled. Assessments for effectiveness and tolerability were conducted at each visit. The primary effectiveness measure was the mean change in PHQ-15 total score, from baseline to the end of treatment. Secondary effectiveness measures were the mean changes in total scores on the Beck Depression Inventory (BDI) and the 12-item General Health Questionnaire (GHQ-12), from baseline to the end of treatment. A total of 45 subjects were enrolled; of them, 28 were randomly assigned to receive fluoxetine and 17 to receive sertraline. The total score on the PHQ-15 from baseline to the end of treatment significantly decreased in the fluoxetine (- 10.7, p < 0.0001) and sertraline (- 10.3, p < 0.0001) treatment groups, with no between-group difference (F = 0.0701, p = 0.7924). Overall, both treatments were well tolerated and no serious adverse event was reported. This study suggests that both agents may have a potential role in the treatment of USD. A double-blind, placebo-controlled trial and/or head-to-head comparison study with larger samples are required to draw more definite conclusions.
| Original language | English |
|---|---|
| Pages (from-to) | 437-444 |
| Number of pages | 8 |
| Journal | Progress in Neuro-Psychopharmacology and Biological Psychiatry |
| Volume | 32 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2008 Feb 15 |
Fingerprint
Keywords
- Fluoxetine
- Open-label
- Patient Health Questionnaire
- Sertraline
- Undifferentiated somatoform disorder
ASJC Scopus subject areas
- Biological Psychiatry
- Pharmacology
Cite this
Fluoxetine versus sertraline in the treatment of patients with undifferentiated somatoform disorder : A randomized, open-label, 12-week, parallel-group trial. / Han, Changsu; Pae, Chi Un; Lee, Bun Hee; Ko, Young-Hoon; Masand, Prakash S.; Patkar, Ashwin A.; Jung, In Kwa.
In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 32, No. 2, 15.02.2008, p. 437-444.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Fluoxetine versus sertraline in the treatment of patients with undifferentiated somatoform disorder
T2 - A randomized, open-label, 12-week, parallel-group trial
AU - Han, Changsu
AU - Pae, Chi Un
AU - Lee, Bun Hee
AU - Ko, Young-Hoon
AU - Masand, Prakash S.
AU - Patkar, Ashwin A.
AU - Jung, In Kwa
PY - 2008/2/15
Y1 - 2008/2/15
N2 - The present study was conducted to compare the effectiveness and tolerability of fluoxetine and sertraline in the treatment of undifferentiated somatoform disorder (USD), using the Patient Health Questionnaire (PHQ-15), which was specifically designed for assessing the severity of somatic symptoms. A randomized, 12-week, open-label trial of fluoxetine (10-60 mg/d) and sertraline (25-350 mg/d) in patients with USD was conducted. Six visits, at baseline and weeks 1, 2, 4, 8, and 12, were scheduled. Assessments for effectiveness and tolerability were conducted at each visit. The primary effectiveness measure was the mean change in PHQ-15 total score, from baseline to the end of treatment. Secondary effectiveness measures were the mean changes in total scores on the Beck Depression Inventory (BDI) and the 12-item General Health Questionnaire (GHQ-12), from baseline to the end of treatment. A total of 45 subjects were enrolled; of them, 28 were randomly assigned to receive fluoxetine and 17 to receive sertraline. The total score on the PHQ-15 from baseline to the end of treatment significantly decreased in the fluoxetine (- 10.7, p < 0.0001) and sertraline (- 10.3, p < 0.0001) treatment groups, with no between-group difference (F = 0.0701, p = 0.7924). Overall, both treatments were well tolerated and no serious adverse event was reported. This study suggests that both agents may have a potential role in the treatment of USD. A double-blind, placebo-controlled trial and/or head-to-head comparison study with larger samples are required to draw more definite conclusions.
AB - The present study was conducted to compare the effectiveness and tolerability of fluoxetine and sertraline in the treatment of undifferentiated somatoform disorder (USD), using the Patient Health Questionnaire (PHQ-15), which was specifically designed for assessing the severity of somatic symptoms. A randomized, 12-week, open-label trial of fluoxetine (10-60 mg/d) and sertraline (25-350 mg/d) in patients with USD was conducted. Six visits, at baseline and weeks 1, 2, 4, 8, and 12, were scheduled. Assessments for effectiveness and tolerability were conducted at each visit. The primary effectiveness measure was the mean change in PHQ-15 total score, from baseline to the end of treatment. Secondary effectiveness measures were the mean changes in total scores on the Beck Depression Inventory (BDI) and the 12-item General Health Questionnaire (GHQ-12), from baseline to the end of treatment. A total of 45 subjects were enrolled; of them, 28 were randomly assigned to receive fluoxetine and 17 to receive sertraline. The total score on the PHQ-15 from baseline to the end of treatment significantly decreased in the fluoxetine (- 10.7, p < 0.0001) and sertraline (- 10.3, p < 0.0001) treatment groups, with no between-group difference (F = 0.0701, p = 0.7924). Overall, both treatments were well tolerated and no serious adverse event was reported. This study suggests that both agents may have a potential role in the treatment of USD. A double-blind, placebo-controlled trial and/or head-to-head comparison study with larger samples are required to draw more definite conclusions.
KW - Fluoxetine
KW - Open-label
KW - Patient Health Questionnaire
KW - Sertraline
KW - Undifferentiated somatoform disorder
UR - http://www.scopus.com/inward/record.url?scp=38749088722&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38749088722&partnerID=8YFLogxK
U2 - 10.1016/j.pnpbp.2007.09.014
DO - 10.1016/j.pnpbp.2007.09.014
M3 - Article
C2 - 17950970
AN - SCOPUS:38749088722
VL - 32
SP - 437
EP - 444
JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry
JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry
SN - 0278-5846
IS - 2
ER -